NOACs for treatment of venous thromboembolism in clinical practice

被引：21

作者：

Schulman, Sam ^{[1
,2
]}

Singer, Daniel ^{[3
,4
]}

Ageno, Walter ^{[5
]}

Casella, Ivan B. ^{[6
]}

Desch, Marc ^{[7
]}

Goldhaber, Samuel Z. ^{[4
,8
]}

机构：

[1] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada

[2] McMaster Univ, Hamilton, ON, Canada

[3] Massachusetts Gen Hosp, Boston, MA 02114 USA

[4] Harvard Med Sch, Boston, MA 02114 USA

[5] Univ Insubria, Varese, Italy

[6] Univ Sao Paulo, Sao Paulo, Brazil

[7] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany

[8] Brigham & Womens Hosp, Boston, MA 02115 USA

来源：

THROMBOSIS AND HAEMOSTASIS | 2017年 / 117卷 / 07期

基金：

美国国家卫生研究院;

关键词：

Venous thromboembolism; non-vitamin K oral anticoagulants; observational studies; recurrence; bleeding; adherence; VITAMIN-K ANTAGONISTS; NONVALVULAR ATRIAL-FIBRILLATION; XA INHIBITOR THERAPY; REAL-WORLD DATA; ORAL ANTICOAGULANTS; POSTTHROMBOTIC SYNDROME; DABIGATRAN ETEXILATE; NONSURGICAL PATIENTS; DAILY CARE; WARFARIN;

D O I：

10.1160/TH17-01-0065

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Randomised controlled trials have provided important information on the efficacy and safety of the non-vitamin K antagonist oral anticoagulants (NOACs) for treatment of venous thromboembolism (VTE), leading to registration and increasing use in clinical practice. Many questions remain to be answered, and observational studies are often more suitable for answering "real-world" questions than randomised controlled trials. Patient satisfaction, quality of life, and adherence and persistence in clinical practice with the drug regimen can only be assessed with an open-label design. Evaluation of risk for long-term sequelae of the disease requires much longer follow-up than is possible in registration trials. Treatment patterns and utilisation of health care resources can be assessed from observations in the clinical practice setting. We will review published as well as currently active observational studies with NOACs in VTE, with or without a comparator anticoagulant. These studies are based on cohorts of different sizes, registries, or administrative health care databases. We will also discuss some limitations in analysis and interpretation of observational studies.

引用

页码：1317 / 1325

页数：9

共 40 条

[1] RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate [J].

Ageno, Walter ;

Casella, Ivan B. ;

Han, Chee Kok ;

Raskob, Gary E. ;

Schellong, Sebastian ;

Schulman, Sam ;

Singer, Daniel E. ;

Kimura, Karen ;

Tang, Wenbo ;

Desch, Marc ;

Goldhaber, Samuel Z. .

THROMBOSIS AND HAEMOSTASIS, 2017, 117 (02) :415-421

[2] Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study [J].

Ageno, Walter ;

Mantovani, Lorenzo G. ;

Haas, Sylvia ;

Kreutz, Reinhold ;

Monje, Danja ;

Schneider, Jonas ;

Van Eickels, Martin ;

Gebel, Martin ;

Zell, Elizabeth ;

Turpie, Alexander G. G. .

LANCET HAEMATOLOGY, 2016, 3 (01) :E12-E21

[3] XALIA: Rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis [J].

Ageno W. ;

Mantovani L.G. ;

Haas S. ;

Kreutz R. ;

Haupt V. ;

Schneider J. ;

Turpie A.G.G. .

Thrombosis Journal, 12 (1)

[4] The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry [J].

Agnelli G. ;

Gitt A.K. ;

Bauersachs R. ;

Fronk E.-M. ;

Laeis P. ;

Mismetti P. ;

Monreal M. ;

Willich S.N. ;

Wolf W.-P. ;

Cohen A.T. ;

Brodmann M. ;

Rief P. ;

Eischer L. ;

Stoshikj S. ;

Hirschl M. ;

Weinmann S. ;

Marschang P. ;

Abbadie F. ;

Achkar A. ;

Addala A. ;

Adnet F. ;

Alexandra J.-F. ;

Aquilanti S. ;

Belhassane A. ;

Benaroya A. ;

Berremili T. ;

Grenot M.C. ;

Birr V. ;

Holtea D. ;

Bonnin C. ;

Bosler F. ;

Durand M.-G.B. ;

Brisot D. ;

Brousse C. ;

De La Fuente T. ;

Cayman R. ;

Cazaubon M. ;

Champion O. ;

Chanut M. ;

Chevalet P. ;

Connault J. ;

Durant C. ;

Constans J. ;

Cordeanu M. ;

Couturaud F. ;

Lacut K. ;

De Dedker L. ;

Decoulx E. ;

Derrien B. ;

Diamand J.-M. .

Thrombosis Journal, 13 (1)

[5]

[Anonymous], 2016, WHY PROPENSITY SCORE

[6] Evaluation of anticoagulation selection for acute venous thromboembolism [J].

Badreldin, Hisham ;

Nichols, Hunter ;

Rimsans, Jessica ;

Carter, Danielle .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 43 (01) :74-78

[7] Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series [J].

Beyer-Westendorf, Jan ;

Michalski, Franziska ;

Tittl, Luise ;

Hauswald-Doerschel, Susann ;

Marten, Sandra .

LANCET HAEMATOLOGY, 2016, 3 (10) :E480-E488

[8] Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy [J].

Beyer-Westendorf, Jan ;

Michalski, Franziska ;

Tittl, Luise ;

Hauswald-Doerschel, Susann ;

Marten, Sandra .

THROMBOSIS AND HAEMOSTASIS, 2016, 115 (06) :1234-1236

[9] Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry [J].

Beyer-Westendorf, Jan ;

Gelbricht, Vera ;

Foerster, Kati ;

Ebertz, Franziska ;

Roellig, Denise ;

Schreier, Thomas ;

Tittl, Luise ;

Thieme, Christoph ;

Haensel, Ulrike ;

Koehler, Christina ;

Werth, Sebastian ;

Kuhlisch, Eberhard ;

Stange, Thoralf ;

Roeder, Ingolf ;

Weiss, Norbert .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (04) :908-917

[10] Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry [J].

Beyer-Westendorf, Jan ;

Foerster, Kati ;

Pannach, Sven ;

Ebertz, Franziska ;

Gelbricht, Vera ;

Thieme, Christoph ;

Michalski, Franziska ;

Koehler, Christina ;

Werth, Sebastian ;

Sahin, Kurtulus ;

Tittl, Luise ;

Haensel, Ulrike ;

Weiss, Norbert .

BLOOD, 2014, 124 (06) :955-962

← 1 2 3 4 →